Matinas BioPharma
MTNB
51 hedge funds and large institutions have $5.61M invested in Matinas BioPharma in 2023 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
66% more capital invested
Capital invested by funds: $3.37M → $5.61M (+$2.24M)
9% more funds holding
Funds holding: 47 → 51 (+4)
0% less ownership
Funds ownership: 0.24% → 0.24% (-0%)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$127K |
| 2 |
CCM
Connective Capital Management
Palo Alto,
California
|
+$71.7K |
| 3 |
AWA
Arkadios Wealth Advisors
Atlanta,
Georgia
|
+$50.8K |
| 4 |
VF
Virtu Financial
New York
|
+$36.8K |
| 5 |
Renaissance Technologies
New York
|
+$35.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$98.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$86.7K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$62.1K |
| 4 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
-$23.7K |
| 5 |
Squarepoint
New York
|
-$19.2K |
MTNB Hedge Fund Activity: Q4 2023 in Review
51 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2023, worth a combined $5.61M — up 66% from $3.37M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new MTNB positions and 6 closed out — a net gain of 4 holders — while 8 added to existing stakes and 10 trimmed.
The largest buyer was Vanguard Group, adding an estimated $127K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $98.1K sold.
- 51 institutional investors held Matinas BioPharma (MTNB) as of Q4 2023, up from 47 in Q3 2023.
- Funds reported $5.61M of Matinas BioPharma stock for Q4 2023, up 66% quarter-over-quarter.
- 10 funds opened new Matinas BioPharma positions in Q4 2023 and 6 closed out, a net change of +4 holders.
- The largest Matinas BioPharma buyer in Q4 2023 was Vanguard Group, an estimated $127K added.
- The largest Matinas BioPharma seller in Q4 2023 was Jacobs Levy Equity Management, an estimated $98.1K sold.
Based on aggregated 13F filings for Q4 2023.